A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease
Abstract Antibody‐mediated removal of aggregated β‐amyloid (Aβ) is the current, most clinically advanced potential disease‐modifying treatment approach for Alzheimer's disease. We describe a quantitative systems pharmacology (QSP) approach of the dynamics of Aβ monomers, oligomers, protofibrils...
Main Authors: | Hugo Geerts, Mike Walker, Rachel Rose, Silke Bergeler, Piet H. van derGraaf, Edgar Schuck, Akihiko Koyama, Sanae Yasuda, Ziad Hussein, Larisa Reyderman, Chad Swanson, Antonio Cabal |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-04-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Online Access: | https://doi.org/10.1002/psp4.12912 |
Similar Items
-
Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease
by: Seiichi Hayato, et al.
Published: (2022-12-01) -
Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model
by: Hugo Geerts, et al.
Published: (2023-09-01) -
Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study
by: Eric McDade, et al.
Published: (2022-12-01) -
QSP Designer: Quantitative systems pharmacology modeling with modular biological process map notation and multiple language code generation
by: Richard J. Matthews, et al.
Published: (2023-07-01) -
Learn–confirm in model‐informed drug development: Assessing an immunogenicity quantitative systems pharmacology platform
by: Linnea C. Franssen, et al.
Published: (2023-02-01)